JP Morgan Chase
COAG

JP Morgan Chase’s Hemab Therapeutics COAG Stock Holding History

JP Morgan Chase’s Portfolio COAG Stock Details COAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.3M Buy
+1,152,420
New +$31.8M ﹤0.01% 1599

Other funds holding COAG

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

JP Morgan Chase's COAG Position: Q2 2026 in Review

JP Morgan Chase opened a new position in Hemab Therapeutics (COAG) in Q2 2026: 1,152,420 shares worth $42.3M. The stake represents ﹤0.01% of the portfolio and ranks #1599 among its holdings.

48 funds tracked by Wall St. Rank hold COAG as of Q2 2026.

  • JP Morgan Chase held 1,152,420 shares of Hemab Therapeutics worth $42.3M as of Q2 2026.
  • Hemab Therapeutics was a new JP Morgan Chase position in Q2 2026.
  • Hemab Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1599 holding.
  • 48 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.